Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
$0.01
$0.01
$0.00
$0.04
N/AN/A107,789 shs25,449 shs
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
$0.00
-9.1%
$0.01
$0.00
$0.15
N/AN/A1.28 million shs1.09 million shs
LBPSW
4D pharma
$0.00
$0.04
$1.29
N/AN/A20,931 shsN/A
Sanofi stock logo
SNYNF
Sanofi
$113.69
+2.4%
$109.43
$91.81
$122.03
N/AN/A5,246 shs579 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
0.00%-2.60%-6.25%-16.67%-11.76%
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
0.00%0.00%-85.71%-80.00%-98.36%
LBPSW
4D pharma
0.00%0.00%0.00%0.00%0.00%
Sanofi stock logo
SNYNF
Sanofi
+2.42%+6.80%+3.05%+5.27%+18.99%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/AN/AN/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Sanofi stock logo
SNYNF
Sanofi
0.8767 of 5 stars
0.02.01.74.01.80.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
0.00
N/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
0.00
N/AN/AN/A
LBPSW
4D pharma
0.00
N/AN/AN/A
Sanofi stock logo
SNYNF
Sanofi
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/AN/AN/AN/AN/A
LBPSW
4D pharma
$522KN/AN/AN/AN/AN/A
Sanofi stock logo
SNYNF
Sanofi
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/A0.00N/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Sanofi stock logo
SNYNF
Sanofi
N/A$3.0836.86N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/AN/AN/AN/A
Sanofi stock logo
SNYNF
Sanofi
$2.802.46%N/A90.78%N/A

Institutional Ownership

CompanyInstitutional Ownership
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/A
LBPSW
4D pharma
N/A
Sanofi stock logo
SNYNF
Sanofi
30.06%

Insider Ownership

CompanyInsider Ownership
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/A
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
N/A
LBPSW
4D pharma
N/A
Sanofi stock logo
SNYNF
Sanofi
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
7N/AN/ANot Optionable
4Front Ventures Corp. stock logo
FFNTF
4Front Ventures
460N/AN/ANot Optionable
LBPSW
4D pharma
N/AN/AN/ANot Optionable
Sanofi stock logo
SNYNF
Sanofi
91,600N/AN/ANot Optionable

Recent News About These Companies

Goldman Sachs Reaffirms Their Hold Rating on Sanofi (SNYNF)
Barclays Keeps Their Buy Rating on Sanofi (SNYNF)
Jefferies Remains a Buy on Sanofi (SNYNF)
Goldman Sachs upgrades Sanofi (SNYNF) to a Hold
Bernstein Keeps Their Buy Rating on Sanofi (SNYNF)
Berenberg Bank Reaffirms Their Buy Rating on Sanofi (SNYNF)
Deutsche Bank Remains a Hold on Sanofi (SNYNF)
Sanofi (SNYNF) Gets a Buy from UBS
Positive Report for Sanofi (SNYNF) from DZ BANK AG
Bernstein Remains a Buy on Sanofi (SNYNF)
UBS Sticks to Its Buy Rating for Sanofi (SNYNF)

Media Sentiment Over Time

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNFW

$0.0075 0.00 (0.00%)
As of 04/30/2025 01:52 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

4Front Ventures stock logo

4Front Ventures OTCMKTS:FFNTF

$0.0020 0.00 (-9.09%)
As of 04/30/2025 03:20 PM Eastern

4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates through THC Cannabis and CBD Wellness segments. THC Cannabis segment engages in the cultivation, production, manufacturing, and distribution of THC cannabis products to owned dispensaries and third party retailers; and provision of ancillary services. This segment sells equipment, supplies, and intellectual property to cannabis producers; and leases real estate properties. The CBD Wellness segment sells non-THC hemp derived products. In addition, it operates dispensaries in the Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.

4D pharma NASDAQ:LBPSW

4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Sanofi stock logo

Sanofi OTCMKTS:SNYNF

$113.69 +2.69 (+2.42%)
As of 04/30/2025 11:48 AM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.